Skip to content

News & Resources

Featured Stories

Siren Biotechnology Announces FDA Clearance of First IND, Advancing Company to Clinical Stage Read More
Media Coverage | Posted on 5.19.26
How a Biotech CEO Turned 1,600 Everyday Investors Into Backers—and Raised $4 Million
Press Releases | Posted on 4.24.26
Siren Biotechnology Publishes Foundational AAV Immuno-Gene Therapy Data and Announces Presentations at ASGCT 2026
Press Releases | Posted on 3.23.26
Siren Biotechnology Announces FDA Clearance of Investigator-Initiated IND to Advance Phase 1 Study in Recurrent High-Grade Glioma
Press Releases | Posted on 2.23.26
Siren Biotechnology Receives FDA Fast Track Designation for SRN-101 for the Treatment of Recurrent High-Grade Glioma
Press Releases | Posted on 1.28.26
Siren Biotechnology Announces FDA Clearance of First IND, Advancing Company to Clinical Stage
Press Releases | Posted on 1.7.26
Siren Biotechnology to Showcase Clinical-Stage Momentum at Major 2026 Healthcare Conferences
Media Coverage | Posted on 9.26.25
Siren Biotechnology named a 2025 Most Fundable Company
Press Releases | Posted on 5.12.25
Siren Biotechnology to Present Universal AAV Immuno-Gene Therapy Data at the 2025 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Biopharma Dive
Media Coverage | Posted on 5.11.25
Siren, a gene therapy startup, tests unconventional alternative to venture funding
Genetic Engineering & Biotechnology News
Media Coverage | Posted on 5.10.25
Signal Alert: Startup Seeks Community Funders for AAV Immuno-Gene Therapy